Compare ADMA Biologics Inc (ADMA) vs Micron Technology, Inc. (MU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Micron Technology, Inc. — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Micron Technology, Inc. trades at $932.38 (market cap $1.06T). The key difference: Micron Technology, Inc. is far larger — about 497.7× ADMA Biologics Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | MU | |
|---|---|---|
Market Cap | $2.13B | $1.06T |
Sector | Health | Technology |
52-Week High | $20.38 | $1.21K |
52-Week Low | $7.60 | $104.88 |
Enterprise Value | $2.20B | $1.04T |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Micron Technology (MU) trades at $938.38, down 3.81% amid a sector-wide chip stock selloff, despite strong fundamentals including a 22.84% net margin and three consecutive quarterly earnings beats. The stock shows a bullish technical trend with support near $933, while analyst consensus remains strongly positive with a $1,540 price target. Recent news highlights AI-driven demand and new supply deals with Ford and GM, though competition and cyclicality pose risks.
Outlook is positive given robust earnings growth and AI memory demand, but investors face volatility from memory market cycles and competitive pressures. The stock offers upside to analyst targets if execution continues, yet macroeconomic and sector rotations could drive near-term swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
